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Legionnaires’
Disease and Travel
in Europe 
To the Editor: The European
Working Group for Legionella
Infections (EWGLINET) conducts
epidemiologic surveillance of
Legionnaires’ disease cases associat-
ed with travel (1) and provides epi-
demiologic typing markers of
Legionella pneumophila among refer-
ence laboratories in collaborating
countries. The procedures and criteria
of notification are found in the
Guidelines for Control and Prevention
of Travel Associated Legionnaires’
Disease (2). However, establishing
the association of >1 case of this dis-
ease and a specific tourist accommo-
dation site is difficult because of low
attack rates and dispersal of people
from the source of infection during
the incubation period.
Collaboration promoted by this
working group encourages the
exchange of data instead of cultures.
This distinction is critical when
research is conducted on travel-asso-
ciated Legionnaires’disease, in which
strains from patients and environmen-
tal sources of infection studied are in
different laboratories.
The value of such information is
shown in a complex case study that
was recently investigated. During July
and August 2005, two patients with
Legionnaire’s disease living in 2
countries in Europe were reported to
EWGLINET. Patient 1 was a 45-year-
old woman who traveled in France
and Spain July 1–6, 2005. Her symp-
toms started on July 6, 2005, when
she was in Girona, Spain, where she
was hospitalized. Patient 2 was a 56-
year-old woman who traveled in
Spain and France August 16–21,
2005. Her symptoms started on
August 8, 2005, when she was in
France, where she was hospitalized.
Both patients tested positive for L.
pneumophila serogroup 1 by specific
urinary antigen test and culture, but
they recovered and were discharged.
After routine notification to EWG-
LINET, it was established from the
list of accommodation sites provided
by the 2 patients that they each had
stayed for 1 night at the same hotel in
a French city within a 45-day interval.
This finding led us to identify a clus-
ter according to the definition in use
(2 cases associated with the same
accommodation within 2 years) (2).
However, patient 2 spent 1 day in
August in Zaragoza, Spain, during
which an outbreak of Legionnaires’
disease in the city affected 30 persons.
Thus, illness in patient 2 could have
been associated with the Zaragoza
outbreak. Alternatively, both patients
could have contracted the illness inde-
pendently at different sites. Before
onset, patient 1 stayed 5 days in her
private residence in Girona and
patient 2 visited 3 other hotels.
As soon as cultures from the 2
patients were available, the National
Reference Laboratories of France and
Spain shared their respective micro-LETTERS
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biologic results. Since both strains
were identified as L.  pneumophila
serogroup 1, we performed sequence-
based typing (SBT) (3) of 6 genes
(flaA,  pilE,  asd,  mip,  mompS, and
proA) by using the protocol and data-
base of EWGLINET. Both isolates
showed identical SBT patterns
(2,3,18,15,2,1).
Isolates from 4 patients in the
Zaragoza outbreak were identified at
the Spanish Reference Laboratory as
L.  pneumophila serogroup 1
(Philadelphia monoclonal antibody
type) and had identical SBT patterns
(3,4,1,1,14,9). Collaboration between
public health authorities in France and
Spain enabled us to eliminate the
association of patient 2 with the
Zaragoza outbreak and establish an
association of both patients with the
same site in France. Control measures
were taken at the hotel, but we could
not obtain environmental cultures for
comparison with those of the patients.
Lack of environmental data prevented
investigation of the relationship with
the other accommodation sites visited.
The SBT method provides robust
genotyping with high discriminatory
power (index of discrimination >0.94)
(3). This method is less effective at
discriminating between strains than
pulsed-field gel electrophoresis (4),
but it shows excellent reproducibility
and may be useful in epidemiologic
investigation of outbreaks caused by
L. pneumophila. The availability of an
online database with accessible infor-
mation is key for sharing results and
determining the geographic distribu-
tion of isolates that cause
Legionnaires’ disease (4,5).
This study demonstrates the criti-
cal role of sharing results between
countries that participate in a network.
Agreement is essential on a standard-
ized questionnaire that includes more
information on the patient’s exposure
to a disease. Moreover, despite the
performance of the urine antigen test,
cultures of clinical samples should be
encouraged by clinicians and microbi-
ologists. This step would permit use
of techniques, such as SBT, in refer-
ence laboratories and sharing of
results. Our investigation would have
been more difficult without this tech-
nique in identifying the site where the
infection potentially originated.
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Influenza A Virus
PB1-F2 Gene
To the Editor: Recently, Chen and
co-workers described the expression
of an 11th influenza A virus protein,
designated PB1-F2 because this pro-
tein is encoded in the +1 open reading
frame of the segment-2 RNA (1).
Later, Chen et al. presented a prelimi-
nary analysis of 336 PB1 sequences
from GenBank (2). We have extended
the work on PB1-F2 and analyzed
1,864 partial and complete segment-2
sequences deposited in GenBank;
these sequences belong to 79 influen-
za A virus subtypes. In summary, the
following 8 observations should
receive attention: 
First, the size of PB1-F2 polypep-
tides ranges from 79 to 101 amino
acids (aa); most isolates encode ver-
sions of either 87 or 90 aa. Because
polypeptides of 79 aa are located
within mitochondria, their truncation
has no effect on the protein function.
The frequency of the 79-aa PB1-F2 is
≈5%.
Second, a functional PB1-F2 is
expressed by 92% of all segment-2
sequences, i.e., a polypeptide >78 aa.
The proportion of intact PB1-F2
varies according to host (humans
90%, swine 76%, other mammals
100%, birds 95%).
Third, the H1N1 subtype compris-
es 3 genetic lineages. One clade has 2
branches: 1 branch includes the
human viruses, with the pandemic
1918 virus at its root; the other branch
includes the classic swine viruses.
The third clade represents the
European porcine isolates. Although
all classic swine sequences have a
truncated PB1-F2 (in-frame stop
codons after 11, 24, and 35 codons),
the early human isolates (H1N1
sequences from 1918 through 1947)
have an intact PB1-F2. After 1956,
however, a mutation became preva-
lent such that the recent sequences
starting from A/Beijing/1/56 termi-
nate after 57 codons. An exception to
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